GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Humanwell Healthcare Group Co 600079.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

19.52

+0.05%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Humanwell Healthcare Group Co

Its shares trade on Shanghai under the ticker 600079.SS. It has been listed since 6 June 1997. In the fiscal year to 31 December 2025, it reported revenue of CN¥23.96bn and net income of CN¥1.86bn. At that date it held total assets of CN¥36.75bn and shareholders' equity of CN¥18.91bn.

Humanwell Healthcare (Group) Co., Ltd. engages in the research and development, production, and sale of medical products. The company is headquartered in Wuhan, Hubei. The Company’s products are categorized into chemical drugs, chemical raw material medicines, traditional Chinese medicines, biological medicines and others. The firm also provides medical instruments. The firm distributes its products in both domestic market and to overseas markets.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
6 Jun 1997
Employees
16,070

Leadership

Pay as last reported

  • Mr. Hansheng ZhouChairman of the Board, since 2017CN¥1.8m
  • Mr. Xiafei DengPresident, Acting Secretary of the Board, Director, since 1998CN¥7.2m
  • Ms. Yajun WuChief Financial Officer, Vice PresidentCN¥2.1m
  • Mr. Wentao DuVice PresidentCN¥4.1m
  • Ms. Li'e LiVice President, Chief EngineerCN¥3.7m
  • Mr. Qianlun LiVice PresidentCN¥2.0m
  • Mr. Qiang YinVice PresidentCN¥2.0m
  • Mr. Qun YuVice PresidentCN¥3.7m
  • Mr. Hongjie ZhangVice PresidentCN¥5.0m
  • Mr. Weidong DengDirector
  • Mr. Xiaohua HuangDirector
  • Mr. Jie LiDirector, since 2003CN¥5.7m

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
62
Environment
79
Social
44
Governance
64
Direct emissions (scope 1)
19,500 t
Energy emissions (scope 2)
106,000 t
Women in the workforce
43.72238%
Carbon reduction policy
Yes
Human rights policy
Yes

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Wuhan, Hubei with 16,070 employees
  • Produces and sells medical products including chemical drugs and traditional Chinese medicines
  • Distributes products domestically and internationally

Weaknesses

  • No specific weaknesses mentioned in the provided information
  • No details on financial performance or market share provided
  • No information on product quality or regulatory compliance

Opportunities

  • Expanding into overseas markets for medical products
  • Growth potential in pharmaceutical sectors including biological medicines
  • Research and development of new medical products

Threats

  • No specific threats mentioned in the provided information
  • No details on competition or market saturation
  • No information on regulatory changes affecting pharmaceutical industry

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.